24 Sep 2013 07:00
Scancell Holdings Plc
('Scancell')
Investor Update Agenda
Scancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, is to host an Investor Update on Tuesday, 1 October 2013. Details of the event are:
Location | FTI Consulting Holborn Gate 26 Southampton Buildings London, WC2A 1PB
|
10.45 | Registration with refreshments
|
11.00 | Introduction David Evans, Scancell Non-Executive Chairman
|
11.05 | Cancer immunotherapy Prof Peter Stern, Head of the Immunology Group, Paterson Institute for Cancer Research, University of Manchester
|
11.20 | Scancell corporate update Dr Richard Goodfellow, Joint CEO of Scancell
|
11.30 | SCIB1 trial update and introduction to Moditope™ Prof Lindy Durrant, Joint CEO of Scancell
|
11.45 | Q&A
|
12.00 | Interactive panel discussion Led by Prof Karol Sikora, Dean of Medicine , University of Buckingham; Honorary Consultant Oncologist at Hammersmith Hospital
Panellists include:
Prof Lindy Durrant, Prof Peter Stern, Dr Steve Chan, Consultant Oncologist, City Hospital, Nottingham University and Prof Christian Ottensmeier, Dept. of Experimental Medicine, University of Southampton
|
12.45 | Buffet lunch
|
13.30 | Close
|
For Further Information:
Dr Richard Goodfellow, Joint CEO Professor Lindy Durrant, Joint CEO | Scancell Holdings Plc Scancell Holdings Plc | + 44 (0) 20 7831 3113 |
Camilla Hume/Stephen Keys | Cenkos Securities | + 44 (0) 20 7397 8900 |
Mo Noonan/Eleanor Clarke | FTI Consulting | + 44 (0) 20 7831 3113 |
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope™ technology platforms. Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.
Scancell's ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity. The Directors believe that the Moditope™ platform could play a major role in the development of safe and effective cancer immunotherapies in the future.
Scancell Holdings (SCLP)